Osimertinib anti-cancer drug. A female patient taking an oral osimertinib tablet labelled AZ80, sold under the trade name Tagrisso. Osimertinib is used in the treatment of non-small cell lung carcinoma (NSCLC), and is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Patients taking this drug may develop resistance after approximately 10 months, and it can cause harm to the foetus so should be avoided by pregnant women. Osimertinib was approved for use by the EU in February 2016.